1. Terminally ill patients due to underlying cardiac, cancer or severe debilitating neurological disease including coma;

2. Hospitalization expected to be \< 96 hours due to medical improvement;

3. Interstitial lung disease;

4. Correction of QTc values obtained by 12 lead EKG using Fredericia's formula (QTcF) \> 450 ms;

5. History of hypotension (mean arterial blood pressure \< 65 mmHg), unrelated to CoVID-19 infection;

6. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 3 times upper limit of normal;

7. Participating concurrently on another clinical trial for the experimental treatment of COVID-19;

8. Active chemotherapy use;

9. Pregnant and/or lactating women.

Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19